The National Reconstruction Fund Corporation has committed $150 million to Brandon Capital to accelerate Australian medical innovation commercialisation, according to an announcement on Thursday. The investment will be allocated to Brandon Capital’s BioCatalyst 6 fund and will support early and late-stage Australian medical science companies developing therapeutics, medical devices and vaccines. NRFC chief executive David…
Brisbane-based biotechnology company Vaxxas published new research on Wednesday showing promising results for its needle-free vaccine delivery technology. The company’s high-density microarray patch (HD-MAP) – a small patch containing thousands of tiny projections coated with vaccine – successfully delivered a DNA-based COVID-19 vaccine in animal testing, according to research published in the science journal Heliyon.…
Brisbane biotechnology company Vaxxas has completed enrolment for testing a needle-free vaccine patch against avian influenza.
Moderna has opened the Southern Hemisphere’s only mRNA vaccine manufacturing site in Victoria, aiming to make 100 million doses a year.
Needle free biotechnology company Vaxxas has announced that the United States National Institutes of Health (NIH) has granted the company a licence to a vaccine antigen candidate (DS2), designed for use in prophylactic vaccines against Respiratory Syncytial Virus (RSV). RSV is a common contagious virus affecting the lungs and breathing passages which causes an estimated…
Japan’s Ministry of Health, Labor and Welfare has approved biotechnology manufacturer CSL and Arcturus Therapeutics’ new Covid-19 vaccine against the JN.1 strain of the disease. The ministry approved for sale the two companies’ ‘updated self-amplifying mRNA Covid-19 vaccine for protection against JN.1 Strain’, to be distributed in Japan by Meiji Seika Pharma. According to CSL…
IDT Australia secures Sanofi contract Pharmaceutical development company IDT Australia has secured a follow on contract with pharma giant Sanofi Australia for preclinical formulation, development and manufacture of Sanofi’s messenger RNA (mRNA). The contract, worth up to $4 million, continues the company’s advancement of mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables…
Australia’s most successful manufacturer, biotechnology company CSL today reported net profit after tax of $2.64 billion for the 12 months ended 30 June 2024, up 25 percent on a constant currency basis. Net profit after tax (NPATA) was $2.91 billion, up 15 percent on revenue up 11 percent to $14.8 billion. CSL’s Chief Executive Officer…
Fleet on hiring spree Small satellite business Fleet Space Technologies is hiring for 11 positions, the company’s co-founder and CEO announced on Monday. In a statement on Linkedin, Flavia Tata Nardini posted about the positions vacant, listing Key Account Executive – Salt Lakes (US)m Senior Sales Executive – Macquarie Arc (AUS), Sales Engineer (APAC), Data…
More rocket launches planned for Koonibba Test Range German rocket manufacturer Hyimpulse is negotiating further space launches from Southern Launch’s South Australian launch facilities following the successful launch its SL1 sub-orbital vehicle from the Koonibba Test Range near Ceduna, SA (pictured). The launch tested Hyimpulse’s novel propulsion technology. The company now plans further launches from…